Theratechnologies Inc trades in the stock market under the ticker symbol of THER. Search for the ticker of any public company above using the 'Get Ticker' search in red.

Who is Theratechnologies Inc?

Theratechnologies Inc., a specialty pharmaceutical company, engages in the discovery and development of therapeutic peptide products with a focus on growth-hormone releasing factor (GRF) peptides. Its primary product is EGRIFTA (tesamorelin for injection), an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, which is marketed in the United States, Latin America, Africa, the Middle East, Europe, Russia, South Korea, Taiwan, and Thailand. The company is also conducting a Phase 2 study of tesamorelin for the treatment of muscle wasting in chronic obstructive pulmonary disease. In addition, it is developing compounds for the treatment of acute kidney injury and certain cancers. The company was founded in 1993 and is headquartered in Montreal, Canada.

69 Employees
Last Reported Date: 02/8/12
Founded in 1993
Last $0.37 USD
Change Today -0.025 / -6.33%
Volume 61.9K
As of 4:30 PM 10/26/12 All times are local (Market data is delayed by at least 15 minutes).

theratechnologies inc (THER) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/27/11 - $3.35
52 Week Low
10/26/12 - $0.36
Market Cap
Average Volume 10 Days
Shares Outstanding
THER Does Not Pay Dividends
THER:US Historical Stock Quote
THER:US Advanced Stock Chart

Related News

No related news articles were found.

theratechnologies inc (THER) Related News

No Related News Found

theratechnologies inc (THER) Key Developments

Theratechnologies Inc. Announces Management Changes

Theratechnologies Inc. announced that John-Michel T. Huss will be leaving his role as president and chief executive officer and as director of the company, effective immediately. On an interim basis, Luc Tanguay, senior executive vice president and chief financial officer, will fulfill the duties of president and chief executive officer. Mr. Tanguay has been a member of the management team since 1996 and a member of the Board of Directors since 1993.

Theratechnologies Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended August 31, 2012

Theratechnologies Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended August 31, 2012. For the quarter, the company reported total revenues of CAD 3,822,000 compared to CAD 3,517,000 a year ago. Negative results from operating activates was CAD 896,000 compared to CAD 4,644,000 a year ago. Net loss before income taxes was CAD 685,000 compared to CAD 4,201,000 a year ago. Net loss was CAD 698,000 or CAD 0.01 per basic and diluted share compared to CAD 4,170,000 or CAD 0.07 per basic and diluted share a year ago. Cash generated from operating activates was CAD 491,000 compared to cash used in operating activates of CAD 9,175,000 a year ago. For the nine months period, the company reported total revenues of CAD 9,668,000 compared to CAD 10,518,000 a year ago. Negative results from operating activates was CAD 10,330,000 compared to CAD 16,821,000 a year ago. Net loss before income taxes was CAD 9,585,000 compared to CAD 16,140,000 a year ago. Net loss was CAD 9,599,000 or CAD 0.16 per basic and diluted share compared to CAD 16,043,000 or CAD 0.26 per basic and diluted share a year ago. Cash used in operating activates was CAD 11,878,000 compared to CAD 24,896,000 a year ago. Acquisition of property, plant and equipment was CAD 69,000 compared to CAD 182,000 a year ago.

Theratechnologies Inc. Provides Follow-Up Regulatory Update on Tesamorelin

Theratechnologies Inc. provided an update regarding the progress of marketing authorization application activities for tesamorelin for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada, Latin America and Europe. Theratechnologies and its commercial partner in Canada, Actelion Pharmaceuticals Canada Inc., received a notice of non-compliance from Health Canada in June 2012. The notice contained follow-up questions regarding long-term safety, the proposed patient population and indication. Theratechnologies and Actelion responded to the additional questions within the prescribed 90-day period. Health Canada has confirmed that the screening of the New Drug Submission (NDS) is complete and that the regulatory review is now under way. The company expects to receive Health Canada's final decision regarding the NDS within the statutory period of 150 days as per Health Canada's regulations. Theratechnologies and its commercial partner in Latin America, sanofi, have been able to address all technical deficiencies identified by Brazil's National Health Surveillance Agency (ANVISA) following an audit of its Montreal-based third-party manufacturing site in June 2012. Following reception of the audit report, the company met with the manufacturer and identified and developed appropriate corrective measures. The corrective measures proposed by ANVISA have been agreed to by the third-party manufacturer and are currently being implemented. The document evidencing compliance with the corrective measures will be sent to the Brazilian regulatory authorities by sanofi in the coming weeks. The final step in the manufacturing assessment will be a conformational audit by ANVISA. Theratechnologies was advised by sanofi that the filing in Venezuela made in June 2012 was deemed incomplete for technical reasons by local authorities. Theratechnologies will support sanofi with corrective measures and the company expect sanofi to resubmit the file in due course. As a result, the review process will then begin anew.

Most Popular on

The Plot to Destroy America's Beer
The Great Internet Firewall of China
The Five Scariest Airports to Land a Plane
Microsoft Sees a New Image of Itself in Windows 8
How to Weaponize Office Supplies: Jörg Sprave
More News

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THER:US $0.37 USD -0.025

THER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for THER.

Industry Analysis


Industry Average

Valuation THER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.7x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x

Post a JobJobs

    We are currently experiencing technical difficulties. Please try again later.
Simply Hired

Sponsored Links

No related news found for this Theratechnologies Inc.
Subject Author Date
ENER does look good david6876 2012-10-17 07:35:17
Pipper Jaffrey Downgrade? tmccune2 2012-10-17 07:35:03
ther / atsi goodbucks71 2012-10-17 07:34:53
Interesting Comments xecvp2b 2012-10-17 07:34:41
HEY BIOACTIVE seansharkey 2012-10-17 07:34:33
at least we're getting a better premium gumburcules 2012-10-17 07:34:24
closing aceputseller2000 2012-10-17 07:34:09
Any chance a Medtronic or J&J would bean5boston 2012-10-17 07:33:56
BYE BYE THER -YOU HAVE BEEN bean5boston 2012-10-17 07:33:47
is it time to sell the rest of my share therasensation 2012-10-17 07:33:38
Call Options Still Moving xecvp2b 2012-10-17 07:33:29
Medtronic guardian sensor plaster22 2012-10-17 07:33:18
To my THER friends..... BooksNWorms 2012-10-17 07:33:05
$27 since Jan - What's going on here? dpblue2 2012-10-17 07:32:54
Checks? tractorpullermom 2012-10-17 07:32:41
###<#>For trading u need mind only not money###<#> quincy.dyerckehndcrpzzo 2012-10-17 07:32:36
#<<<##penny stocks#<<<## blanca_hornwhjdejsjcqbs 2012-10-17 07:32:27
#<>#><a bit of a subjective concept#<>#>< mel_traniyjjprwsvruuzedn 2012-10-17 07:32:20
<>#<>>Forex Auto money System Real way to make money<>#<>> dinoherring76 2012-10-17 07:32:10
><><<#increase knowledge about stock trading.><><<# owensilva48 2012-10-17 07:31:55
><<#>#Read this and do well in stock><<#># gerry.grayjdzbpdts 2012-10-17 07:31:46
test beachcm65 2012-10-17 07:31:36
BUY SONT seansharkey 2012-10-17 07:31:26
How to value THER just_the_facts101 2012-10-17 07:31:06
Shorters Ha ha josh200112002 2012-10-17 07:30:53
  • 1
  • 0
  • 0

Get our Stock Market & Financial Investment news alerts in your inbox

Read our full disclaimer and privacy policy